Technical Analysis for IRWD - Ironwood Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 12.0 4.90% 0.56
IRWD closed up 4.9 percent on Tuesday, April 23, 2019, on 71 percent of normal volume.

Earnings due: May 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical IRWD trend table...

Date Alert Name Type % Chg
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup 4.90%
Oversold Stochastic Weakness 4.90%
New Downtrend Bearish 6.76%
Oversold Stochastic Weakness 6.76%
Down 3 Days in a Row Weakness 7.82%
Down 4 Days in a Row Weakness 7.82%
Down 5 Days in a Row Weakness 7.82%
Oversold Stochastic Weakness 7.82%

Older signals for IRWD ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Medical Specialties Cardiovascular Diseases Central Nervous System Disorders Gastroenterology Peptides European Union Gastrointestinal Diseases Irritable Bowel Syndrome Digestive Diseases Constipation Gastrointestinal Disorders Human Therapeutic Products Ironwood Pharmaceuticals
Is IRWD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 21.2
52 Week Low 9.07
Average Volume 1,471,627
200-Day Moving Average 14.9975
50-Day Moving Average 13.282
20-Day Moving Average 12.24
10-Day Moving Average 11.599
Average True Range 0.5681
ADX 25.96
+DI 21.1429
-DI 29.1306
Chandelier Exit (Long, 3 ATRs ) 12.4457
Chandelier Exit (Short, 3 ATRs ) 12.6243
Upper Bollinger Band 13.8176
Lower Bollinger Band 10.6624
Percent B (%b) 0.42
BandWidth 25.777778
MACD Line -0.5342
MACD Signal Line -0.508
MACD Histogram -0.0262
Fundamentals Value
Market Cap 1.79 Billion
Num Shares 150 Million
EPS -0.98
Price-to-Earnings (P/E) Ratio -12.24
Price-to-Sales 8.05
Price-to-Book 441.52
PEG Ratio -0.24
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.01
Resistance 3 (R3) 12.93 12.51 12.84
Resistance 2 (R2) 12.51 12.26 12.55 12.78
Resistance 1 (R1) 12.26 12.10 12.39 12.34 12.73
Pivot Point 11.84 11.84 11.91 11.88 11.84
Support 1 (S1) 11.59 11.59 11.72 11.67 11.27
Support 2 (S2) 11.17 11.43 11.21 11.22
Support 3 (S3) 10.92 11.17 11.16
Support 4 (S4) 11.00